Tibbutt D A, Chesterman C N
Drugs. 1976;11(3):161-92. doi: 10.2165/00003495-197611030-00001.
Pulmonary thromboembolism is a widespread problem and is an important cause of death in patients with a variety of medical and surgical conditions. There have been few significant advances in the understanding of the aetiology beyond additional evidence confirming the importance of Virchow's triad. An impressive list of epidemiological associations has been compiled, however. Some knowledge of the natural progression of the disease is required as an aid in the understanding of the application of the therapeutic and prophylactic measures available in the management of pulmonary embolism. It would seem that at least two-thirds of pulmonary emboli are non-fatal, and in these cases the natural resolution, even of comparatively large embolic masses, is very efficient in patients without pre-existing cardiopulmonary disease. Diagnosis may prove difficult and most ancillary investigations are of questionable value. On the other hand, pulmonary radio-isotope scanning is far more specific and pulmonary angiography is a comparatively simple and complication-free diagnostic procedure. Prophylaxis is a real and practical aim, especially following surgery or myocardial infarction. In these groups widespread clinical trials of prophylactic measures have been made possible by the objective radio-iosotope screening techniques. Mechanical means of preventing venous stasis and anticoagulation appear effective. In addition, low-dose subcutaneous heparin seems to be as useful as heparin in conventional dosage. Apart from conventional supportive therapy, there are three major approaches to the treatment of pulmonary embolism. Heparin remains the mainstay, particularly in the less severe cases, hopefully preventing propogation of thrombosis and recurrence of embolism, thus allowing resolution to take place. Thrombolytic therapy with streptokinase or urokinase is capable of producing far more rapid dissolution of pulmonary emboli with consequent theoretical advantages over heparin. No reduction in mortality has been shown using thrombolytic therapy. Patients who fail to respond satisfactorily to acute resuscitative measures may require pulmonary embolectomy.
肺血栓栓塞是一个普遍存在的问题,是各种内科和外科疾病患者死亡的重要原因。除了进一步证实魏尔啸三联征重要性的证据外,在病因学的认识上几乎没有重大进展。然而,已经列出了一长串令人印象深刻的流行病学关联。需要了解该疾病的自然病程,以帮助理解肺栓塞治疗和预防措施在管理中的应用。似乎至少三分之二的肺栓塞是非致命性的,在这些病例中,对于没有心肺疾病史的患者,即使是相对较大的栓子团块,自然溶解也非常有效。诊断可能很困难,大多数辅助检查的价值存疑。另一方面,肺放射性同位素扫描特异性更强,而肺血管造影是一种相对简单且无并发症的诊断方法。预防是一个切实可行的目标,尤其是在手术后或心肌梗死后。在这些人群中,客观的放射性同位素筛查技术使得预防措施的广泛临床试验成为可能。预防静脉淤滞的机械方法和抗凝似乎是有效的。此外,低剂量皮下注射肝素似乎与常规剂量肝素一样有效。除了常规的支持治疗外,治疗肺栓塞有三种主要方法。肝素仍然是主要治疗手段,特别是在病情较轻的病例中,有望防止血栓形成的扩展和栓塞的复发,从而实现溶解。用链激酶或尿激酶进行溶栓治疗能够更迅速地溶解肺栓塞,理论上比肝素更具优势。但溶栓治疗并未显示出死亡率降低。对急性复苏措施反应不佳的患者可能需要进行肺动脉栓子切除术。